Objective-The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) remains to be elucidated.
C hronic thromboembolic pulmonary hypertension (CTEPH) is one of the distinct disease entities of pulmonary hypertension (PH), characterized by obstruction of major pulmonary artery by organized thrombus and pulmonary vascular remodeling. [1] [2] [3] [4] CTEPH leads to increased pulmonary vascular resistance, progressive PH, and right heart failure to death. 2, 5 CTEPH has been considered to occur after acute pulmonary embolism or recurrent pulmonary embolism; however, it is also known that few patients have deep vein thrombosis or episodes of acute pulmonary embolism. 6 There are few reports about the association between CTEPH and coagulation abnormality, such as antiphospholipids antibody 7 and fibrinogen mutation. 8, 9 Furthermore, it has been reported that plasma levels of tissue-type plasminogen activator (tPA) and those of plasminogen activator inhibitor (PAI) were not related to the severity of CTEPH. 10 Thus, it remains to be examined whether fibrinolysis capacity is impaired in CTEPH and if so, what molecular mechanism(s) is involved. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma carboxypeptidase inhibitor produced by liver. TAFI is activated by thrombin, thrombin/thrombomodulin complex, and plasmin, whereas activated form of TAFI (TAFIa) removes the C-terminal lysines from fibrin and reduces the binding of tPA and plasmin to fibrin. 11 It has been demonstrated that activated platelets support the generation of thrombin, 12 which will cause activation of TAFI. TAFI has been reported to be a risk factor of recurrent deep vein thrombosis, 13 although it remains unknown whether TAFI is involved in the pathogenesis of CTEPH.
Current guidelines recommend that patients with CTEPH should be treated with life-long anticoagulation and some drugs specific for pulmonary arterial hypertension (PAH). 2 Recently, it has been reported that riociguat, a stimulator of soluble guanylate cyclase, significantly improves exercise capacity and pulmonary vascular resistance in patients with CTEPH. 14 Although pulmonary thromboendarterectomy is an established surgical treatment for central-type CTEPH, 15 recent studies have demonstrated that percutaneous transluminal pulmonary angioplasty (PTPA) is effective for distal-type CTEPH. 16, 17 However, as the precise mechanisms of CTEPH have not been fully elucidated, fundamental therapy remains to be developed.
In this study, we thus examined whether fibrinolysis capacity is impaired in CTEPH patients with a special reference to TAFI and if so, whether TAFI is directly involved in the pathogenesis of CTEPH in humans.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Clinical Characteristics of Study Subjects
Clinical characteristics of the study subjects are shown in Table. There were no significant differences in the baseline characteristics among the 3 groups except body mass index and the use of pulmonary vasodilators (epoprostenol, oral prostaglandin I 2 analog, endothelin receptor antagonists, and phosphodiesterase-V inhibitors) and warfarin (Table) . Although body mass index was higher in patients with CTEPH than in PAH or non-PH patients, the prevalence of obesity (body mass index >25) was comparable among the groups (P=0.25). Endothelin receptor antagonists were used more in patients with PAH than in patients with CTEPH. In pulmonary hemodynamics, pulmonary arterial pressure and pulmonary vascular resistance were significantly higher in PAH and CTEPH than in non-PH, which were comparable between PAH and CTEPH (Table) . Systolic blood pressure was significantly lower in PAH and CTEPH than in non-PH (Table) .
Resistance to Fibrinolysis in Whole Blood Clot Lysis Assay
The whole blood clot lysis assay was performed using a modification of the method by Frenkel et al. 18 In this study, 8 non-CTEPH patients were treated with warfarin, and 33 non-CTEPH patients were not treated with warfarin. The extent of clot remaining after 4 hours with 100 ng/mL monteplase was comparable between the 2 groups (24.9±13.0 versus 27.8±7.4%, P=0.31; Figure I in the online-only Data Supplement). Thus, the results were not affected by the treatment with warfarin in this study. There was no significant difference in the extent of clot remaining after 4 hours in response to urokinase among the 3 groups, although both CTEPH and PAH tended to be resistant to 1.0 U/mL of urokinase compared with non-PH ( Figure 1A ). In contrast, importantly, in the whole blood clot lysis assay with monteplase, the extent of clot remaining after 4 hours was significantly higher in CTEPH than in other 2 groups ( Figure 1B) ; the extent of clot remaining after 4 hours in response to 100 ng/ mL of monteplase in non-PH, PAH, and CTEPH was 26.5±12.8, 24.6±11.4, and 41.9±15.2%, respectively (non-PH versus CTEPH, P<0.01; PAH versus CTEPH, P<0.01; Figure 1B ). These results suggest that the clot of CTEPH is more resistant to fibrinolysis than that of non-PH or PAH.
Resistance to Fibrinolysis in Plasma Clot Lysis Assay
The plasma clot lysis assay was performed using a modification of the previous methods. 19, 20 In the plasma clot lysis assay, the clot lysis time of non-PH, PAH, and CTEPH was 616 (514-714), 647 (502-844), and 788 (657-1116) seconds (median [interquartile ranges]), respectively ( Figures 1C-1F ), indicating that the plasma clot of CTEPH tended to be more resistant than that of non-PH or PAH. Wet weight of the whole blood clot was comparable among the 3 groups ( Figure 1G ).
Elevated Plasma Levels of TAFI in CTEPH
Plasma levels of total PAI-1 and plasminogen were comparable among the 3 groups (Figure 2A and 2B). In contrast, plasma levels of TAFI were significantly higher in CTEPH than in non-PH or PAH ( Figure 2C ; Figure II in the onlineonly Data Supplement). Furthermore, plasma levels of TAFI positively correlated with the extent of clot remaining after 4 hours in all patients (P=0.02, R=0.30; Figure 2D ) and positively correlated with the clot lysis time (P=0.01, R=0.42) in all patients ( Figure 2E ). Furthermore, we analyzed the correlation between plasma levels of TAFI and clot lysis time in patients with CTEPH. Interestingly, plasma TAFI levels tended to be positively correlated with clot lysis time (P=0.07; Figure III in the online-only Data Supplement). Moreover, addition of human TAFI to 6 different plasmas of healthy volunteers, significantly increased the clot lysis time compared with those without human TAFI ex vivo ( Figure 2F ).
Elevated Platelet-Derived TAFI in CTEPH
Blood from the pulmonary artery of patients was collected and was centrifuged to obtain platelet pellet. The supernatant (the plasma) was discarded, and platelet pellet was resuspended in isotonic citrate buffer. Platelets were centrifuged, Figure 1 . Clot lysis assay with blood from the pulmonary artery. A-C, The whole blood clot lysis assay with urokinase or monteplase in patients with non-pulmonary hypertension (PH) (n=19), patients with pulmonary arterial hypertension (PAH, n=22), and patients with chronic thromboembolic PH (CTEPH, n=25). A, Percentage of the clot remaining after 4 hours (mean±SD) with normal saline as a control and 1.0 and 10 U/mL urokinase. B, Percentage of the clot remaining after 4 hours (mean±SD) with normal saline as a control and 10 and 100 ng/mL monteplase. C and D, The clot lysis time (↔; clot lysis time) with plasma clot lysis assay in patients with non-PH (n=10), patients with PAH (n=21), and patients with CTEPH (n=25). Representative results of plasma clot lysis assay in patients with non-PH (C), patients with PAH (D), and patients with CTEPH (E). F, The results of clot lysis time in 3 groups are shown with box plot. G, The weight of the clots (mean±SD) was comparable among the 3 groups. Statistical significance was determined with Tukey-Kramer test. *P<0.01 vs non-PH, †P<0.01 vs PAH. and the supernatant (the first supernatant) was discarded and resuspended in isotonic citrate buffer, which procedure was repeated (the second supernatant). TAFI was detected in the plasma and the first supernatant, but not in the second supernatant, by immunoblotting method ( Figure 3A) , indicating that TAFI from the plasma was completely removed by washing platelet pellet twice. After stimulation with 0.5 U/ mL of thrombin at 25°C for 20 minutes, TAFI was detected in the supernatant (the third supernatant), which was considered as platelet-derived TAFI. Although TAFI was released from platelets in all the 3 groups, the TAFI levels in PAH and CTEPH were 1.4 and 2.1 folds compared with non-PH, respectively (non-PH versus CTEPH, P<0.01; PAH versus CTEPH, P<0.05), indicating that the levels of platelet-derived TAFI were significantly higher in CTEPH than in non-PH and PAH ( Figure 3B and 3C ).
Effects of PGE 1 and TAFIa Inhibitor on Resistance of Clot to Fibrinolysis in CTEPH
To confirm that the resistance to monteplase of the clot in patients with CTEPH was related to the TAFI pathway, we examined the effects of PGE 1 (a platelet inactivator) and CPI-2KR (TAFIa inhibitor) 21 in the whole blood clot lysis assay. First, we confirmed that PGE 1 was able to inhibit platelet activation (in response to tapping every 3 minutes for 20 minutes at 25°C) by the flow cytometric analysis ( Figure 4A and 4B). Treatment with PGE 1 significantly decreased the extent of clot remaining after 4 hours when cotreated with 100 ng/ mL of monteplase (29.5±13.8 versus 37.8±13.4%, P<0.01; Figure 4C ), indicating that the resistance to monteplase of the clots from patients with CTEPH is related to platelet activation. Next, we examined the effects of CPI-2KR (1.25 mg/ mL) on the extent of clot remaining after 4 hours. When cotreated with monteplase (100 ng/mL), the TAFIa inhibitor dose dependently improved the extent of clot remaining after 4 hours ( Figure 4D) . Then, the plasma levels of TAFI positively correlated with the improvement rate of the extent of clot remaining after 4 hours (P=0.02, R=0.52) ( Figure 4E ). Moreover, after the treatment with CPI-2KR (1.25 mg/mL), the extent of clot remaining after 4 hours (change ratio) was significantly higher in patients with CTEPH compared with the controls (15.3±11.0 versus 3.1±7.0%, P<0.05; Figure IV in the online-only Data Supplement). These results indicate that the resistance to monteplase of the clot from patients with CTEPH is directly related to the TAFI activation in the plasma.
No Change in Plasma Levels of TAFI After Hemodynamic Improvement by PTPA
Mean pulmonary arterial pressure was significantly reduced after PTPA (39.0±7.9 mm Hg versus 24.9±4.4 mm Hg, P<0.01; Figure 5A ). In contrast, the plasma levels of TAFI did not change significantly before and after the treatment Figure 5B ). These results suggest that the increased plasma levels of TAFI in patients with CTEPH are not the results of increased pulmonary arterial pressure.
Genotype of CPB2
It has been reported that single-nucleotide polymorphisms of CPB2 (eg, −1120 G/T, rs799916836 and −1583 A/T, rs108737) were related to the elevation of plasma levels of TAFI. [22] [23] [24] Indeed, it has been demonstrated that Thr325/Ile (rs192644738) is related with the active state of TAFI. 24 We examined these single-nucleotide polymorphisms in 17 patients with CTEPH. Interestingly, we found the minor allele of rs7999168 in 4 patients with CTEPH (24%), the minor allele of rs1926447 in 4 patients (24%), and the minor allele of rs1087 in 6 patients (35%).
Discussion
The novel findings of this study were as follows: (1) the clot from patients with CTEPH was resistant to fibrinolysis with monteplase, (2) plasma levels of TAFI were elevated in patients with CTEPH and were not changed after hemodynamic improvement with PTPA, (3) the levels of TAFI released from platelets were increased in patients with CTEPH, and (4) the resistance to monteplase was improved by PGE 1 and TAFIa inhibitor. Taken together, these results indicate that TAFI is substantially involved in the resistance to thrombus fibrinolysis in patients with CTEPH. To the best of our knowledge, this is the first study demonstrating that plasma levels of TAFI is high in patients with CTEPH and are correlated with the resistance to clot lysis in CTEPH.
Baseline Characteristics of Patients With CTEPH
Endothelin receptor antagonists were used more in patients with PAH than in patients with CTEPH. There are few reports that these are effective in CTEPH. 25 Endothelin receptor antagonists improve the hemodynamics in CTEPH but do not improve the exercise capacity, 26 which was the reasons for the limited use of endothelin receptor antagonist in patients with CTEPH. Although body mass index was higher in patients with CTEPH than in PH or non-PH patients in this study, the prevalence of obesity was comparable among the groups. Thus, we consider that the present results were not affected by the difference in the prevalence of obesity although obesity is related to the plasma levels of TAFI. 27 Furthermore, there were no patients with CTEPH who had protein C or S deficiency. Although we have no data for Factor V Leiden, there was no patients with CTEPH who had Factor V Leiden in the previous study of Japan.
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Effects of Warfarin on Fibrinolysis
In this study, all patients with CTEPH were treated with warfarin. Thus, we examined the effects of warfarin to fibrinolysis. We found that fibrinolysis was unaffected by the treatment with warfarin. It was previously reported that warfarin promotes fibrinolysis. 29 The control range of prothrombin timeinternational normalized ratio (PT-INR) is lower in Japan than in other countries. Indeed, in this study, the range of PT-INR in patients with warfarin was 1.63±0.39. This might be the potential reason why the treatment with warfarin did not affect fibrinolysis in this study.
Resistance to Fibrinolysis in Patients With CTEPH
Although a few studies examined fibrinolysis capacity in patients with CTEPH, 8, 9 this study clearly demonstrates that patients with CTEPH show enhanced resistance to fibrinolysis compared with non-PH and PAH and that TAFI is directly involved in the resistance to fibrinolysis in CTEPH. Importantly, both CTEPH and PAH tended to be resistant to urokinase compared with non-PH, suggesting that the fibrin of CTEPH and PAH was resistant to plasmin, as previously reported by Miniati et al. 30 Furthermore, we demonstrated that fibrinolysis activity to urokinase and monteplase was different in CTEPH, where the clot was resistant to fibrinolysis with tPA, but not to urokinase, a consistent finding with the previous report that plasma levels of tPA antigen were elevated ≤53.0 ng/mL after 15 minutes of experimentally induced venous occlusion. 10 Plasma clot lysis assay also showed that the clot of CTEPH was more resistant to fibrinolysis compared with those of non-PH and PAH. Maximum absorbance differed among the patients. It has been demonstrated that the maximum absorbance A, TAFI was confirmed in the plasma and first supernatant, but not in the second supernatant after the stimulation with 0.5 U/mL thrombin at 20°C for 20 minutes. TAFI was reconfirmed in the third supernatant, which was defined as the levels of TAFI released from platelets. B, Representative results of TAFI released from non-pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), and chronic thromboembolic PH (CTEPH) patients. C, Quantitative analysis of the levels of TAFI (mean±SD) released from platelets in non-PH, PAH, and CTEPH patients (n=10 each). Statistical significance was determined with Tukey-Kramer test.
is correlated with the plasma levels of fibrinogen. 31 Thus, the difference of maximum absorbance among the patients might be related to the different plasma levels of fibrinogen.
Elevated Plasma Levels of TAFI as a Pathogenesis of CTEPH
Carboxypeptidase N and TAFI are members of a large family of zinc metalloproteases. 32 Carboxypeptidase N is also a liver-derived plasma carboxypeptidase and exists as an active form in plasma. Although carboxypeptidase N has effects on bradykinin or anaphylatoxins 33 and regulates immune system, TAFI regulates not only immune system but also fibrinolysis. 32 TAFIa removes the C-terminal lysines from fibrin, which reduces the binding of tPA and plasmin to fibrin. 11 Although it has been reported that plasma levels of TAFI can be a risk factor of deep vein thrombosis, 13, 34 this study clearly demonstrates that plasma levels of TAFI are significantly elevated in patients with CTEPH than those of non-PH and PAH. However, the levels of other fibrinolysis antigens, such as PAI-1 and plasminogen, were comparable among the 3 groups, which is consistent with the previous reports. 10 Although PAH has the obstruction of small pulmonary arteries with thrombus, CTEPH has the obstruction of large pulmonary arteries with organized thrombus. This suggests that the mechanism of thrombus formation in CTEPH is different from that of PAH. 35 The present results suggest that TAFI is a new risk factor in CTEPH but not in PAH. Although plasma levels of TAFI correlated with plasma clot lysis time, it only had a weak correlation with whole blood clot lysis time. As previously reported, 29 whole blood clot lysis assay has more factors than plasma clot lysis assay, such as red blood cells and platelets. Importantly, plasma levels of TAFI did not change for 3 months after the hemodynamic improvement with PTPA. These results suggest that the increased plasma levels of TAFI are the cause, but not the simple results, of elevated pulmonary arterial pressure. Furthermore, we analyzed the correlation between plasma levels of TAFI and clot lysis time in patients with CTEPH. Interestingly, plasma TAFI levels tended to be positively correlated with clot lysis time. Thus, further increase of the number of patients with CTEPH enrolled may have determined the relationship between them.
The possible correlation between TAFI and platelets was examined previously 12, 36 because TAFI can be released from activated platelets and cause vascular damage and pathological thrombus formation. 36 It was also demonstrated that TAFI can be more activated on the surface of aggregating platelets and that activated platelets inhibit fibrinolysis through activation of TAFI and clot retraction. 12 In this study, to evaluate the amount of TAFI released from platelets, we washed platelets twice with buffer (first and second supernatants) and completely removed TAFI from the plasma. It has been demonstrated that TAFI released from platelets was only 0.1% of TAFI in the plasma. 36 Moreover, it remains to be elucidated whether TAFI is produced in platelets or took up from the plasma. However, when the clots are formed in vivo, aggregating platelets secrete TAFI into the clots, which will significantly increase the local levels of TAFI and stabilize the clots. Thus, in spite of the small amount of TAFI released from platelets, it is considered that platelet-derived TAFI plays an important role for clot stabilization in vivo. 36 Consistently, we demonstrated that TAFI was released from activated platelets, and its levels were significantly higher in platelets from CTEPH than those from non-PH or PAH. Importantly, Mosnier et al 37 have reported that TAFI was synthesized in megakaryocyte cell lines. Thus, our data may implicate that the increased TAFI released from platelets in patients with CTEPH was, at least part, not from uptake. In addition, the resistance of the clot to monteplase in patients with CTEPH was significantly improved by cotreatment with TAFIa inhibitor peptide or PGE 1 as an inhibitor of activation of platelets.
Genotype of CPB2 in CTEPH
It has been reported that single-nucleotide polymorphisms of CPB2 (eg, −1120 G/T, rs799916836 and −1583 A/T, rs108737) were related to the elevation of plasma levels of TAFI. [22] [23] [24] Moreover, it has been demonstrated that Thr325/Ile (rs192644738) is associated with differences in the stability of the TAFIa. 24 Thus, we performed genotyping of CPB2 in patients with CTEPH.
We found the minor allele of rs7999168 in 4 patients with CTEPH (24%), the minor allele of rs1926447 in 4 patients (24%), and the minor allele of rs1087 in 6 patients (35%). The HapMap with the Asian population found that the prevalence of the minor allele was 0% for rs7999168, 24% for rs1926447, and 42% for rs1087. 38 Thus, it is possible that the prevalence of the minor allele of rs7999168 in patients with CTEPH is higher compared with the standard Asian population. We need to increase the number of patients with CTEPH to elucidate the role of single-nucleotide polymorphism in the pathogenesis of the disorder.
Potential Usefulness of PGE 1 and TAFIa inhibitor in CTEPH
As demonstrated in this study, the resistance of thrombus to fibrinolysis in patients with CTEPH was significantly improved by cotreatment with PGE 1 or TAFIa inhibitor. Continuous intravenous epoprostenol therapy is also effective for CTEPH, especially in the distal type, probably because of its vasodilator effects. 5, 16, 39 The present result suggests that antiplatelet effect of epoprostenol may also contribute to the amelioration of the resistance to fibrinolysis in patients with CTEPH.
We used inhibiting peptide of TAFIa, which is called CPI-2KR. 21 This drug specifically inhibits TAFIa with no off-target effects even at high concentration. 21 Indeed, clot lysis time was shorter by the treatment with 253 μmol/L of CPI-2KR in plasma clot lysis assay. 21 Because CPI-2KR is a peptide, CPI-2KR could have been digested in the whole blood. 21 On the basis of this report, we used CPI-2KR at the concentration of 250 μmol/L and 1.25 mmol/L. However, we need to consider potential off-target effects at high concentration.
Nowadays, we use warfarin or novel oral anticoagulants as anticoagulant therapy to prevent the progression of CTEPH. However, this study suggests that TAFIa inhibitor could be a novel therapeutic agent that may be safer than anticoagulants in terms of bleeding side effects, which frequency (≤3% per year) cannot be ignored.
Study Limitations
Several limitations should be mentioned for this study. First, the number of the study subjects was relatively small. Thus, there was a wide spread of the PAI-1 levels because of the small number of patients. Because it is known that the PAI-1 levels do not change in patients with CTEPH, 10 our main message as to the plasma levels of TAFI may not be influenced by the levels of PAI-1. Second, we had only 1 chance to get the blood from pulmonary artery at the catheterization and we had to experiment whole blood clot lysis assay, plasma clot-lysis assay, the TAFI derived from platelets, and whole blood clot lysis assay with inhibitors using fresh blood. Therefore, as it took a lot of time and blood samples to do all experiments, we were unable to perform all assays at one time in all patients. Thus, we randomly selected patients to perform each assay, which could have caused selection bias in this study.
